12:37 PM EDT, 07/11/2024 (MT Newswires) -- Kane Biotech ( KNBIF ) on Thursday said it signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations for its coactiv+ line of scalp care products.

The five-year non-exclusive agreement will see Omni commercialize Kane's scalp-detoxifier product under the Omni Bioceuticals brand in the medical aesthetics market.

"Kane's scalp-care product line addresses minor health ailments where biofilms are a contributory factor. It contains Kane's patented coactiv+ technology which breaks down bacterial and fungal biofilms and the accumulation of precipitated shampoo films that exacerbate the symptoms associated with common scalp conditions. Kane launched a shampoo, shampoo bar and scalp detoxifier under the DermaKB brand in 2020, as its first products in their new skin care line," the company said.

The company's shares were last seen down $0.005 to $0.145 on the TSX Venture Exchange.

Price: 0.15, Change: -0.01, Percent Change: -3.33